Cohava Gelber

Years Active: 2024-2024
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets (2024)
Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 24 (7) (2024)
Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 24 (7) (2024)

Cohava Gelber.css-eqlu8i{font-size:small;padding-left:4px;}